These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 28027559)

  • 1. The contribution of hereditary thrombophilia to increasing the frequency of thrombosis in patients with Ph negative myeloproliferative neoplasms, including the victims from the Chornobyl accident.
    Mishcheniuk OY; Shkarupa VM; Kostukevich OM; Neumerzhitcka LV; Kravchenko SM; Klymenko SV
    Probl Radiac Med Radiobiol; 2016 Dec; 21():291-311. PubMed ID: 28027559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
    Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
    Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CONTRIBUTION OF THE G1691A ALLELE CARRYING OF THE COAGULATION FACTOR V GENE TO THE DEVELOPMENT OF THROMBOSES IN RADIATION-EXPOSED PATIENTS WITH REACTIVE CHANGES IN PERIPHERAL BLOOD.
    Mishcheniuk OY; Kostiukevych OM; Benkovska LK; Kravchenko OM; Klymenko SV
    Probl Radiac Med Radiobiol; 2020 Dec; 25():502-515. PubMed ID: 33361857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
    Horvat I; Boban A; Zadro R; Antolic MR; Serventi-Seiwerth R; Roncevic P; Radman I; Sertic D; Vodanovic M; Pulanic D; Basic-Kinda S; Durakovic N; Zupancic-Salek S; Vrhovac R; Aurer I; Nemet D; Labar B
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):53-63. PubMed ID: 30301673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical risk factors of thrombosis in patients with Ph-negative myeloproliferative neoplasms, who had experienced radiation exposure due to the Chornobyl accident.
    Mishcheniuk OY; Klymenko SV
    Probl Radiac Med Radiobiol; 2013; (18):232-9. PubMed ID: 25191727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of laboratory hematological parameters for thromboses development in patients with spontaneous and radiation associated Ph negative myeloproliferative neoplasms.
    Mishcheniuk OY; Klymenko SV
    Probl Radiac Med Radiobiol; 2015 Dec; 20():376-98. PubMed ID: 26695916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm.
    Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
    Korean J Intern Med; 2021 Sep; 36(5):1190-1203. PubMed ID: 34289585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexistence of factor V G1691A and factor II G20210A gene mutations in a thrombotic family is associated with recurrence and early onset of venous thrombosis.
    Gemmati D; Serino ML; Moratelli S; Tognazzo S; Ongaro A; Scapoli GL
    Haemostasis; 2001; 31(2):99-105. PubMed ID: 11684865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic thrombophilia has pleiotropic effects in pregnancy.
    Tempfer CB; Riener EK; Hefler LA; Keck C
    Per Med; 2004 Dec; 1(1):105-114. PubMed ID: 29793228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the JAK2 V617F Mutation and Inherited Thrombophilia on the Thrombotic Risk among Patients with Myeloproliferative Disorders.
    Tevet M; Ionescu R; Dragan C; Lupu AR
    Maedica (Bucur); 2015 Mar; 10(1):27-32. PubMed ID: 26225146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
    Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
    Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital.
    Sukrisman L
    J Blood Med; 2022; 13():495-503. PubMed ID: 36118738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
    Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
    Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inherited thrombophilia: a possible cause of in utero vascular thrombosis in children with intestinal atresia.
    Johnson SM; Meyers RL
    J Pediatr Surg; 2001 Aug; 36(8):1146-9. PubMed ID: 11479844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms.
    Barzilai M; Kirgner I; Avivi I; Ellis M; Dally N; Rozovski U; Lavi N
    Eur J Haematol; 2019 Jun; 102(6):504-508. PubMed ID: 30941804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
    Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
    Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients.
    Lee MW; Ryu H; Choi YS; Song IC; Lee HJ; Yun HJ; Sun BJ; Jeong JO; Jo DY
    Blood Res; 2020 Jun; 55(2):77-84. PubMed ID: 32429621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.